Abstract: Antibodies against insulin like growth factor I receptor (IGF-IR), methods for their production, pharmaceutical compositions containing said antibodies, and uses for such antibodies are disclosed. Antibodies against IGF-IR are implicated in antitumor therapy.

Abstract: This invention relates to anti-P-selectin antibodies and, in particular, to anti-P-selectin antibodies and variants thereof that contain an Fc part derived from human origin and do not bind complement factor C1q. These antibodies have new and inventive properties causing a benefit for a patient suffering from critical limb ischemia or peripheral arterial occlusive disease (CLI/PAOD).

Abstract: The current invention is related to a conjugate comprising one or more antifusogenic peptides and an anti-CCR5 antibody (mAb CCR5) characterized in that one to eight antifusogenic peptides are each conjugated to one terminus of the heavy and/or light chains of said anti-CCR5 antibody and to the pharmaceutical use of said conjugate.

Abstract: The current invention is related to a conjugate comprising two or more antifusogenic peptides and an anti-CD4 antibody (mAb CD4) characterized in that one to eight antifusogenic peptides are each conjugated to one terminus of the heavy and/or light chains of said anti-CD4 antibody and to the pharmaceutical use of said conjugate.

Abstract: Antibodies against insulin like growth factor I receptor (IGF-IR), methods for their production, pharmaceutical compositions containing said antibodies, and uses for such antibodies are disclosed. Such antibodies are implicated in antitumor therapy.

Abstract: Antibodies which bind to IGF-IR and inhibit the binding of IGF-I and IGF-II to IGF-IR are characterized. These antibodies are implicated in anti-tumor therapy.

Abstract: The current invention is related to peptide-immunoglobulin-conjugates in which at least two of the termini of the immunoglobulin polypeptide chains are conjugated to a peptide, whereby the peptides can be different, similar or identical. The conjugation is effected on the nucleic acid level.

Abstract: A method for the recombinant production of a heterologous polypeptide in a eukaryotic host cell is described. The host cell comprises an expression plasmid, whereby the expression plasmid comprises in a 5? to 3? direction a) a promoter, b) a nucleic acid encoding a first polypeptide, whose amino acid sequence is selected from Table 1 depending on the first two amino acids of the second polypeptide, c) a nucleic acid encoding a second polypeptide comprising a nucleic acid encoding a heterologous polypeptide, a nucleic acid encoding a linker, and a nucleic acid encoding an immunoglobulin fragment, and d) a 3? untranslated region comprising a polyadenylation signal. Further a plasmid and a kit are described.

Abstract: A method for the recombinant production of a polypeptide by expressing a nucleic acid encoding said polypeptide in a microbial host cell, forming in the cytoplasm of said host cell inclusion bodies containing said polypeptide, and isolating, solubilizing and naturing said polypeptide, characterized in that after fermentation the host cell or the host cell content is incubated at a temperature of 40° C. or higher for at least 10 minutes and subsequently insoluble polypeptide is isolated from the host cell, this method providing an improved yield in inclusion bodies containing the desired polypeptide.

Abstract: This invention relates to anti-P-selectin antibodies and, in particular, to anti-P-selectin antibodies and variants thereof that contain an Fc part derived from human origin and do not bind complement factor C1q. These antibodies have new and inventive properties causing a benefit for a patient suffering from critical limb ischemia or peripheral arterial occlusive disease (CLI/PAOD).

Abstract: A process for the recombinant production of an antifusogenic peptide by expression of a nucleic acid encoding the antifusogenic peptide as a repeat peptide in a microbial host cell to form inclusion bodies which comprise said repeat peptide, comprising the steps of washing the inclusion bodies with a denaturing agent at a pH value of at or below pH 6.5, solubilizing the washed inclusion bodies at a pH value of at least pH 9, and cleaving said repeat peptide to obtain said antifusogenic peptide.

Abstract: There is provided a conjugate comprising the C domain of human gelatinase A (PEX domain, PEX) and one to three poly(ethylene glycol) group(s), said poly(ethylene glycol) group(s) having an overall weight of from about 10 to 40 kDa and being conjugated via primary amino group(s) of said PEX. The conjugates are useful as anticancer agents.

Abstract: Antibodies against insulin like growth factor I receptor (IGF-IR), methods for their production, pharmaceutical compositions containing said antibodies, and uses for such antibodies are disclosed. Such antibodies are implicated in antitumor therapy.

Abstract: A method for the recombinant production of a polypeptide by expressing a nucleic acid encoding said polypeptide in a microbial host cell, forming in the cytoplasm of said host cell inclusion bodies containing said polypeptide, and isolating, solubilizing and naturing said polypeptide, characterized in that after fermentation the host cell or the host cell content is incubated at a temperature of 40° C. or higher for at least 10 minutes and subsequently insoluble polypeptide is isolated from the host cell, this method providing an improved yield in inclusion bodies containing the desired polypeptide.

Abstract: Antibodies which bind to IGF-IR and inhibit the binding of IGF-I and IGF-II to IGF-IR are characterized. These antibodies are implicated in anti-tumor therapy.

Abstract: A chimeric serine protease whose protease domain is composed of two domain halves (half-sides) with a &bgr;-folded sheet structure, wherein the first domain half corresponds to the first domain half of a first serine protease and the second domain half corresponds to the second domain half of a second serine protease, has improved properties and can be readily crystallized.

Abstract: A process for the recombinant production of a protease is characterized by a) transforming a host cell with a recombinant nucleic acid which codes for a zymogenic precursor of a protease containing an autocatalytic cleavage site which does not occur naturally, wherein the active form of the said protease recognizes this cleavage site and cleaves the precursor to form the active protease, b) culturing the host cell in such a way that the zymogenic precursor of the protease is formed in the host cell in the form of inclusion bodies, c) isolating the inclusion bodies and renaturation under such conditions that the protease part of the zymogenic precursor is formed in its natural conformation and d) autocatalytic cleavage of the renatured zymogenic precursor to produce the active protease. This process is suitable for providing recombinant proteases in a simple manner and in large amounts.

Abstract: The present invention concerns muteins of avidin and streptavidin with a reduced binding affinity for biotin as well as their use as interference elimination reagents in methods for the determination of an analyte e.g. in diagnostic tests such as for example immunoassays and nucleic acid hybridization assays. In addition the invention concerns the use of muteins of avidin and streptavidin as systems capable of regeneration for binding biotin e.g. for the analysis of biotinylated molecules, for examining receptor ligand interactions as well as for the affinity purification of biotinylated molecules.

Abstract: The present invention concerns muteins of avidin and streptavidin with a reduced binding affinity for biotin as well as their use as interference elimination reagents in methods for the determination of an analyte e.g. in diagnostic tests such as for example immunoassays and nucleic acid hybridization assays. In addition the invention concerns the use of muteins of avidin and streptavidin as systems capable of regeneration for binding biotin e.g. for the analysis of biotinylated molecules, for examining receptor ligand interactions as well as for the affinity purification of biotinylated molecules.

Abstract: A prokaryotic expression vector including an origin of replication, at least one eukaryotic auxotrophy marker gene which encodes an enzyme required for the synthesis of a product necessary for the survival of at auxotrophic prokaryote under the control of a eukaryotic promoter, a foreign gene under the control of a prokaryotic promoter, and one or more transcription terminators.